Sample A: Cover Page of Thesis, Project, or Dissertation Proposal
Sample A: Cover Page of Thesis, Project, or Dissertation Proposal
Sample A: Cover Page of Thesis, Project, or Dissertation Proposal
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
64. Cropp CS, Lidereau R, Leone A, Liscia D, Cappa AP, Campbell G, Barker E, Le Doussal<br />
V, Steeg PS, Callahan R: NME1 protein expression and loss <strong>of</strong> heterozygosity<br />
mutations in primary human breast tum<strong>or</strong>s. J Natl Cancer Inst 1994, 86(15):1167-<br />
1169.<br />
65. Lamb RF, Going JJ, Pickf<strong>or</strong>d I, Birnie GD: Allelic imbalance at NME1 in<br />
microdissected primary and metastatic human col<strong>or</strong>ectal carcinomas is frequent but<br />
not associated with metastasis to lymph nodes <strong>or</strong> liver. Cancer Res 1996, 56(4):916-<br />
920.<br />
66. Leary JA, Kerr J, Chenevix-Trench G, D<strong>or</strong>is CP, Hurst T, Houghton CR, Friedlander<br />
ML: Increased expression <strong>of</strong> the NME1 gene is associated with metastasis in<br />
epithelial ovarian cancer. Int J Cancer 1995, 64(3):189-195.<br />
67. Miele ME, De La Rosa A, Lee JH, Hicks DJ, Dennis JU, Steeg PS, Welch DR:<br />
Suppression <strong>of</strong> human melanoma metastasis following introduction <strong>of</strong> chromosome<br />
6 is independent <strong>of</strong> NME1 (Nm23). Clin Exp Metastasis 1997, 15(3):259-265.<br />
68. Scholnick SB, Sun PC, Shaw ME, Haughey BH, el-M<strong>of</strong>ty SK: Frequent loss <strong>of</strong><br />
heterozygosity f<strong>or</strong> Rb, TP53, and chromosome arm 3p, but not NME1 in squamous<br />
cell carcinomas <strong>of</strong> the supraglottic larynx. Cancer 1994, 73(10):2472-2480.<br />
69. Toulas C, Mihura J, de Balincourt C, Marques B, Marek E, Soula G, Roche H, Favre G:<br />
Potential prognostic value in human breast cancer <strong>of</strong> cytosolic Nme1 protein<br />
detection using an <strong>or</strong>iginal hen specific antibody. Br J Cancer 1996, 73(5):630-635.<br />
70. Boldrini L, Donati V, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M,<br />
Mussi A, Sant<strong>or</strong>o M, Basolo F et al: Prognostic significance <strong>of</strong> osteopontin expression<br />
in early-stage non-small-cell lung cancer. Br J Cancer 2005, 93(4):453-457.<br />
71. Donati V, Boldrini L, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M,<br />
Mussi A, Sant<strong>or</strong>o M, Basolo F et al: Osteopontin expression and prognostic<br />
significance in non-small cell lung cancer. Clin Cancer Res 2005, 11(18):6459-6465.<br />
72. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M et al:<br />
Overexpression <strong>of</strong> osteopontin is associated with m<strong>or</strong>e aggressive phenotypes in<br />
human non-small cell lung cancer. Clin Cancer Res 2005, 11(13):4646-4652.<br />
73. Hu Z, Xiao T, Lin DM, Guo SP, Zhang ZQ, Di XB, Cheng SJ, Gao YN: [Overexpression<br />
<strong>of</strong> osteopontin in non-small cell lung cancers: its clinical significance].<br />
Zhonghua Zhong Liu Za Zhi 2007, 29(8):591-595.<br />
74. Le QT, Cao H, Koong A, Giaccia A: Comment on: osteopontin as toxic marker.<br />
Radiother Oncol 2006, 78(2):230; auth<strong>or</strong> reply 230-231.<br />
75. Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider<br />
PM, Salonga D, Holscher AH, Danenberg PV: Osteopontin but not osteonectin<br />
161